<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        344-334-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tiplex 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        THIOTEPA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Intravesical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Lyophilisate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1205.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="THYMOORGAN PHARMAZIE GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            THYMOORGAN PHARMAZIE GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tiplex contains the active substance thiotepa, which belongs to a group of medicines called alkylating agents.</p><p>Tiplex is used to prepare patients for bone marrow transplantation. It works by destroying bone marrow cells. This enables the<br />transplantation of new bone marrow cells (haematopoietic progenitor cells), which in turn enable the body to produce healthy blood cells.</p><p>Tiplex can be used in adults and children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Tiplex</strong></p><ul><li>If you are allergic to thiotepa,</li><li>If you are pregnant or think you may be pregnant,</li><li>If you are breast-feeding,</li><li>If you are receiving yellow fever vaccination, live virus and bacterial vaccines.</li></ul><p><strong>Warnings and precautions</strong><br />You should tell your doctor if you have:</p><ul><li>Liver or kidney problems,</li><li>Heart or lung problems,</li><li>Seizures/fits (epilepsy) or have had them in the past (if treated with phenytoin or fosphenytoin).</li></ul><p>Because Tiplex destroys bone marrow cells responsible for producing blood cells, regular blood tests will be taken during treatment to check<br />your blood cell counts.</p><p>In order to prevent and manage infections, you will be given anti-infectives.</p><p>Tiplex may cause another type of cancer in the future. Your doctor will discuss this risk with you.</p><p><strong>Other medicines and Tiplex</strong><br />Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>You must tell your doctor if you are pregnant or you think you may be pregnant before you receive Tiplex. You must not use Tiplex during<br />pregnancy.</p><p>Both women and men using Tiplex must use effective contraceptive methods during treatment.</p><p>Men should not father a child while treated with Tiplex and during the year after cessation of treatment.</p><p>It is not known whether this medicinal product is excreted in breast milk. As a precautionary measure, women must not breast feed during<br />treatment with Tiplex.</p><p>Tiplex can impair male and female fertility. Male patients should seek advice for sperm preservation before therapy is started.</p><p><strong>Driving and using machines</strong><br />It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect your ability to drive and use<br />machines. If you are affected, do not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will calculate the dose according to your body surface or weight and your disease.</p><p><strong>How Tiplex is given</strong></p><p>Tiplex is administered by a qualified healthcare professional as an intravenous infusion (drip in a vein) after dilution of the individual vial.</p><p>Each infusion will last 2‑4 hours.</p><p><strong>Frequency of administration</strong></p><p>You will receive your infusions every 12 or 24 hours. The duration of treatment can last up to 5 days.</p><p>Frequency of administration and duration of treatment depend on your disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>The most serious side effects of thiotepa therapy or the transplant procedure may include:</em></strong></p><ul><li>Decrease in circulating blood cell counts (intended effect of the medicine to prepare you for your transplant infusion)</li><li>Infection</li><li>Liver disorders including blocking of a liver vein</li><li>The graft attacks your body (graft versus host disease)</li><li>Respiratory complications</li></ul><p>Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events.</p><p><em><strong>Side effects of thiotepa may occur with certain frequencies, which are defined as follows:</strong></em><br /><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><ul><li>Increased susceptibility to infection</li><li>Whole-body inflammatory state (sepsis)</li><li>Decreased counts of white blood cells, platelets and red blood cells (anaemia)</li><li>The transplanted cells attack your body (graft versus host disease)</li><li>Dizziness, headache, blurred vision</li><li>Uncontrolled shaking of the body (convulsion)</li><li>Sensation of tingling, pricking or numbness (paraesthesia)</li><li>Partial loss of movement</li><li>Cardiac arrest</li><li>Nausea, vomiting, diarrhoea</li><li>&nbsp;Inflammation of the mucosa of the mouth (mucositis)</li><li>Irritated stomach, gullet, intestine</li><li>Inflammation of the colon</li><li>Anorexia, decreased appetite</li><li>High glucose in the blood</li><li>Skin rash, itching, shedding</li><li>&nbsp;Skin colour disorder (do not confuse with jaundice - see below)</li><li>Redness of the skin (erythema)</li><li>Hair loss</li><li>Back and abdominal pain, pain</li><li>Muscle and joint pain</li><li>Abnormal electrical activity in the heart (arrhythmia)</li><li>Inflammation of lung tissue</li><li>Enlarged liver</li><li>Altered organ function</li><li>Blocking of a liver vein (Veno-Occlusive Disease, VOD)</li><li>Yellowing of the skin and eyes (jaundice)</li><li>Hearing impaired</li><li>Lymphatic obstruction</li><li>High blood pressure</li><li>Increased liver, renal and digestive enzymes</li><li>Abnormal blood electrolytes</li><li>Weight gain</li><li>Fever, general weakness, chills</li><li>Bleeding (haemorrhage)</li><li>Nasal bleeding</li><li>General swelling due to fluid retention (oedema)</li><li>Pain or inflammation at the injection site</li><li>Eye infection (conjunctivitis)</li><li>Decreased sperm cell count</li><li>Vaginal bleeding</li><li>Absence of menstrual periods (amenorrhea)</li><li>Memory loss</li><li>Delaying in weight and height increase</li><li>Bladder disfunction</li><li>Underproduction of testosterone</li><li>Insufficient production of thyroid hormone</li><li>Deficient activity of the pituitary gland</li><li>Confusional state</li></ul><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><ul><li>Anxiety, confusion</li><li>&nbsp;Abnormal bulging outward of one of the arteries in the brain (intracranial aneurysm)</li><li>Creatinine elevated</li><li>Allergic reactions</li><li>Occlusion of a blood vessel (embolism)</li><li>Heart rhythm disorder</li><li>Heart inability</li><li>Cardiovascular inability</li><li>&nbsp;Oxygen deficiency</li><li>Fluid accumulation in the lungs (pulmonary oedema)</li><li>Pulmonary bleeding</li><li>Respiratory arrest</li><li>Blood in the urine (haematuria) and moderate renal insufficiency</li><li>Inflammation of the urinary bladder</li><li>Discomfort in urination and decrease in urine output (disuria and oliguria)</li><li>Increase in the amount of nitrogen components in the blood stream (BUN increase)</li><li>Cataract</li><li>Inability of the liver</li><li>Cerebral haemorrhage</li><li>Cough</li><li>Constipation and upset stomach</li><li>Obstruction of the bowel</li><li>Perforation of stomach</li><li>Changes in muscle tone</li><li>Gross lack of coordination of muscle movements</li><li>Bruises due to a low platelet count</li><li>Menopausal symptoms</li><li>Cancer (second primary malignancies)</li><li>Abnormal brain function</li><li>Male and female infertility</li></ul><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><ul><li>Inflammation and exfoliation of the skin (erythrodermic psoriasis)</li><li>Delirium, nervousness, hallucination, agitation</li><li>Gastrointestinal ulcer</li><li>Inflammation of the muscular tissue of the heart (myocarditis)</li><li>Abnormal heart condition (cardiomyopathy)</li></ul><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li>Increased blood pressure in the arteries (blood vessels) of the lungs (pulmonary arterial hypertension)</li><li>Severe skin damage (e.g. severe lesions, bullae, etc.) potentially involving the full body surface which can be even life-threatening</li><li>Damage to a component of the brain (the so called white matter) which can be even life-threatening (leukoencephalopathy).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store and transport refrigerated (2-8&deg;C). Avoid freeze.</p><p>Store in the original package.</p><p>After reconstitution, the product is stable for 8 hours when stored at 2-8&deg;C.</p><p>After dilution, the product is stable for 24 hours when stored at 2-8&deg;C and for 4 hours when stored at 25&deg;C. From a microbiological point of<br />view, the product should be used immediately.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use.<br />These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is thiotepa.</p><p>Each vial of Tiplex 15 mg Powder for Concentrate for Solution for Infusion contains 15 mg thiotepa.</p><p>Each vial of Tiplex 100 mg Powder for Concentrate for Solution for Infusion contains 100 mg thiotepa.</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tiplex 15 mg and 100 mg Powder for Concentrate for Solution for Infusion is white lyophilized powder in type I clear colorless glass vials with
gray stoppers and dark blue flip-off caps.
Pack size: 1 Vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 4980170<br />Fax: + (966-11) 4980187<br />e-mail: SAPV@hikma.com</p><p><strong>Bulk manufacturer</strong><br />Thymoorgan Pharmazie GmbH<br />Schiffgraben 23<br />38690 Goslar<br />Germany<br />Tel: + (49-5324) 77010<br />Fax: + (49- 5324) 770130</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can<br />also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of<br />this medicine.<br />&bull; Saudi Arabia<br />The National Pharmacovigilance Center (NPC)<br />SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States<br />Please contact the relevant competent authority.<br />&bull; United Arab of Emirates<br />Pharmacovigilance &amp; Medical Device Section<br />P.O. Box: 1853<br />Tel: 80011111<br />Email: pv@mohap.gov.ae<br />Drug Department<br />Ministry of Health &amp; Prevention<br />Dubai</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 09/2023; version number Un2.0.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي تيبلكس على المادة الفعالة ثيوتيبا، والتي تنتمي إلى مجموعة من الأدوية تسمى العوامل المؤلكلة.</p><p dir="RTL">يُستخدم تيبلكس لتهيئة المرضى لزراعة نخاع العظام. وهو يعمل عن طريق تدمير خلايا نخاع العظام. ويتيح ذلك زرع خلايا جديدة لنخاع العظام (الخلايا المكونة للدم)، والتي بدورها تمكن الجسم<br />من إنتاج خلايا دم سليمة.</p><p dir="RTL">يمكن استخدام تيبلكس لدى البالغين والأطفال والمراهقين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم تيبلكس</strong></p><ul dir="rtl"><li>إذا كان لديك حساسية من ثيوتيبا،</li><li>إذا كنتِ حاملاً أو تعتقدين بأنك حاملاً،</li><li>إذا كنتِ مرضعاً،</li><li>إذا كنت تتلقى لقاح الحمى الصفراء، لقاح الفيروس الحي ولقاحات بكتيرية.</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />يجب أن تخبر طبيبك إذا كان لديك:</p><ul dir="rtl"><li>مشاكل في الكبد أو الكلى،</li><li>مشاكل في القلب أو الرئة،</li><li>النوبات/التشنجات )الصرع( أو التي عانيت منها في الماضي )إذا تم علاجها بالفينيتوين أو الفوسفينيتوين(.</li></ul><p dir="RTL">نظراً لأن تيبلكس يدمر خلايا نخاع العظام المسؤولة عن إنتاج خلايا الدم، فسيتم إجراء فحوصات دم منتظمة أثناء العلاج للتحقق من عدد خلايا الدم لديك.</p><p dir="RTL">من أجل الوقاية من العدوى والتعامل معها، سيتم إعطاؤك مضادات العدوى.</p><p dir="RTL">قد يسبب تيبلكس نوعاً آخر من السرطان في المستقبل. سيناقش الطبيب معك هذا الخطر.</p><p dir="RTL"><strong>الأدوية الأخرى وتيبلكس</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى.</p><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت حاملاً أو تعتقدين بأنك حاملاً قبل أخذ تيبلكس. يجب عدم استخدام تيبلكس أثناء الحمل.</p><p dir="RTL">يجب على النساء والرجال الذين يستخدمون تيبلكس استخدام وسائل منع الحمل الفعالة أثناء العلاج.</p><p dir="RTL">يجب على الرجال عدم إنجاب طفل أثناء العلاج بتيبلكس وخلال العام الذي يلي توقف العلاج.</p><p dir="RTL">من غير المعروف إذا ما كان هذا المستحضر الدوائي يُفرَز في حليب الثدي أم لا. كإجراء وقائي، يجب على النساء عدم الإرضاع أثناء العلاج باستخدام تيبلكس.</p><p dir="RTL">يمكن أن يسبب تيبلكس العقم عند الذكور والإناث. يجب على المرضى الذكور طلب المشورة بشأن الحفاظ على الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من المحتمل أن تؤثر بعض التفاعلات العكسية لثيوتيبا مثل الدوخة، الصداع وتشوش الرؤية على قدرتك على القيادة واستخدام الآلات. وإذا كنت مصاباً، لا تقود أو تستخدم الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيحسب طبيبك الجرعة وفقاً لمساحة سطح جسمك أو وزنك ومرضك.</p><p dir="RTL"><strong>طريقة إعطاء تيبلكس</strong></p><p dir="RTL">4 ساعات. - يعطي متخصص مؤهل في الرعاية الصحية تيبلكس على شكل تسريب وريدي (بالتنقيط في الوريد) بعد تخفيف زجاجة منفردة. سيستمر كل تسريب من 2</p><p dir="RTL"><strong>تكرار إعطاء الدواء</strong></p><p dir="RTL">ستتلقى التسريب الخاص بك كل 12 أو 24 ساعة. يمكن أن تستمر مدة العلاج حتى 5 أيام.</p><p dir="RTL">يعتمد تكرار إعطاء الدواء ومدة العلاج على مرضك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong><em>قد تشمل الآثار الجانبية الأكثر خطورة للعلاج بثيوتيبا أو إجراء عملية الزرع ما يلي:</em></strong></p><ul dir="rtl"><li>انخفاض في عدد خلايا الدم المنتشر (التأثير المقصود للدواء لتهيئتك للتسريب لإجراء عملية الزرع)&nbsp;</li><li>العدوى&nbsp;</li><li>اضطرابات الكبد ومنها انسداد وريد كبدي</li><li>مهاجمة الخلايا المزروعة جسمك (مرض مهاجمة الخلايا المزروعة خلايا جسم المستقبل )&nbsp;</li><li>مضاعفات الجهاز التنفسي</li></ul><p dir="RTL">سيراقب طبيبك عدد كريات الدم وإنزيمات الكبد بانتظام لاكتشاف هذه الآثار والتحكم فيها.</p><p dir="RTL"><strong><em>قد تحدث آثاراً جانبية بسبب ثيوتيبا بتكرارات معينة، والتي يمكن تحديدها كما يلي:</em></strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً (قد تؤثر في أكثر من شخص واحد من بين كل 10 أشخاص) </strong></p><ul dir="rtl"><li>قابلية أعلى للإصابة بالعدوى&nbsp;</li><li>حالة التهابية تصيب الجسم بأكمله (تعفن الدم)&nbsp;</li><li>انخفاض عدد خلايا الدم البيضاء، الصفائح الدموية وخلايا الدم الحمراء (فقر الدم)&nbsp;</li><li>مهاجمة الخلايا المزروعة جسمك (مرض مهاجمة الخلايا المزروعة خلايا جسم المستقبل)&nbsp;</li><li>دوخة، صداع، تشوش الرؤية&nbsp;</li><li>ارتعاش الجسم بشكل يصعب السيطرة عليه (تشنج)&nbsp;</li><li>الإحساس بالوخز، النخز أو التنميل (مَذَل)&nbsp;</li><li>فقدان جزئي للحركة&nbsp;</li><li>توقف القلب&nbsp;</li><li>غثيان، قيء، إسهال&nbsp;</li><li>التهاب الغشاء المخاطي للفم (التهاب الغشاء المخاطي)&nbsp;</li><li>تهيج المعدة، المريء، الأمعاء&nbsp;</li><li>التهاب القولون&nbsp;</li><li>فقدان الشهية، نقص الشهية&nbsp;</li><li>ارتفاع نسبة الجلوكوز في الدم&nbsp;</li><li>طفح جلدي، حكة، تقشر جلدي&nbsp;</li><li>اضطراب لون الجلد (لا تخلط بينه وبين اليرقان - انظر أدناه)&nbsp;</li><li>احمرار الجلد (الحُمامَى)&nbsp;</li><li>تساقط الشعر&nbsp;</li><li>ألم في الظهر والبطن، الشعور بالألم&nbsp;</li><li>ألم في العضلات والمفاصل&nbsp;</li><li>نشاط كهربائي غير طبيعي في القلب (عدم انتظام ضربات القلب)&nbsp;</li><li>التهاب أنسجة الرئتين&nbsp;</li><li>تضخم الكبد&nbsp;</li><li>تغير وظيفة العضو&nbsp;</li><li>انسداد وريد كبدي (مرض الانسداد الوريدي)&nbsp;</li><li>اصفرار البشرة والعينين (اليرقان)&nbsp;</li><li>ضعف السمع&nbsp;</li><li>الانسداد اللمفاوي&nbsp;</li><li>ارتفاع ضغط الدم&nbsp;</li><li>زيادة إنزيمات الكبد، الكلى والجهاز الهضمي&nbsp;</li><li>كهارل دم غير طبيعية&nbsp;</li><li>زيادة في الوزن&nbsp;</li><li>حمى، ضعف عام، قشعريرة&nbsp;</li><li>نزف (نزف دموي)&nbsp;</li><li>نزف أنفي</li><li>تورم عام بسبب احتباس السوائل (وذمة)</li><li>ألم أو التهاب في موضع الحقن</li><li>عدوى العين (التهاب الملتحمة)</li><li>قلة عدد خلايا الحيوانات المنوية</li><li>نزف مهبلي</li><li>غياب فترات الحيض (انقطاع الطمث)</li><li>فقدان الذاكرة</li><li>تأخر في زيادة الوزن الطول</li><li>اختلال وظائف المثانة</li><li>نقص إنتاج هرمون التستوستيرون</li><li>عدم إنتاج هرمون الغدة الدرقية بشكل كاف</li><li>قصور نشاط الغدة النخامية</li><li>حالة ارتباك</li></ul><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 10 أشخاص)</strong></p><ul dir="rtl"><li>قلق، ارتباك</li><li>انتفاخ غير طبيعي من أحد شرايين الدماغ (تمدد الأوعية الدموية داخل الجمجمة)</li><li>ارتفاع الكرياتينين</li><li>ردود أفعال تحسسية</li><li>انسداد الأوعية الدموية (الانسداد)</li><li>اضطراب ضربات القلب</li><li>فشل القلب</li><li>فشل الأوعية الدموية</li><li>نقص الأكسجين</li><li>تراكم السوائل في الرئتين (وذمة رئوية)</li><li>نزف رئوي</li><li>توقف التنفس</li><li>دم في البول (بول دموي) وقصور كلوي معتدل</li><li>التهاب المثانة البولية</li><li>عدم الراحة أثناء التبول وانخفاض في كمية البول (عسر التبول وقلة البول)</li><li>زيادة كمية مكونات النيتروجين في مجرى الدم (زيادة نيتروجين اليوريا في الدم)</li><li>إعتام عدسة العين</li><li>فشل الكبد</li><li>نزف دماغي</li><li>سعال</li><li>إمساك واضطراب في المعدة</li><li>انسداد معوي</li><li>ثقب معوي</li><li>تغيرات في التوتر العضلي</li><li>نقص حاد في التناسق الحركي للعضلات</li><li>كدمات نتيجة لانخفاض عدد الصفائح الدموية</li><li>أعراض انقطاع الطمث</li><li>السرطان (الأورام الخبيثة الأولية من النوع الثاني)</li><li>اختلال بوظائف الدماغ</li><li>عقمٌ عند الذكور والإناث</li></ul><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر فيما يصل إلى شخص من بين كل 100 شخص)</strong></p><ul dir="rtl"><li>التهاب وتقشر الجلد (الصدفية المُحَمِّرة للجلد)</li><li>هذيان، عصبية، هلوسة، تَهيُّج</li><li>قرحة مِعديَّة مِعويَّة</li><li>التهاب النسيج العضلي للقلب (التهاب عضلة القلب)</li><li>اضطراب غير طبيعي في القلب (اعتلال عضلة القلب)</li></ul><p dir="RTL"><strong>غير معروفة: لا يمكن تقدير التكرار من البيانات المتاحة</strong></p><ul dir="rtl"><li>ارتفاع ضغط الدم في شرايين (الأوعية الدموية) الرئتين (ارتفاع ضغط الدم الشرياني الرئوي)</li><li>تلف الجلد الشديد (على سبيل المثال، الآفات الشديدة، الفقاعات، وما إلى ذلك) الذي قد يغطي سطح الجسم بالكامل مما قد يهدد الحياة</li><li>تلف بأحد أجزاء الدماغ (ما يسمى بالمادة البيضاء) ما قد يهدد الحياة (اعتلال بيضاء الدِّماغ)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ وينقل داخل الثلاجة (2-8&deg; مئوية). تجنب التجميد.&nbsp;</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">بعد الحل، يكون المستحضر مستقراً لمدة 8 ساعات عند حفظه عند درجة حرارة تتراوح من 2-8&deg; مئوية.</p><p dir="RTL">بعد التخفيف، يكون المستحضر مستقراً لمدة 24 ساعة عند حفظه عند درجة حرارة تتراوح من 2-8&deg; مئوية ولمدة 4 ساعات عند حفظه عند درجة حرارة 25&deg; مئوية. من وجهة النظر الميكروبيولوجية، يجب استخدام المستحضر على الفور.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ثيوتيبا.</p><p dir="RTL">تحتوي كل زجاجة من تيبلكس 15 ملغم مسحوق لتشكيل المركز ثم التخفيف للتسريب<strong> </strong>على 15 ملغم ثيوتيبا.</p><p dir="RTL">تحتوي كل زجاجة من تيبلكس 100 ملغم مسحوق لتشكيل المركز ثم التخفيف للتسريب على 100 ملغم ثيوتيبا.</p><p dir="RTL">لا توجد مكونات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تيبلكس 15 ملغم و100 ملغم مسحوق لتشكيل المركز ثم التخفيف للتسريب هو مسحوق أبيض مجفّف بالتجميد في زجاجات شفافة عديمة اللون من النوع رقم واحد مع سدادات رمادية وأغطية زرقاء داكنة قابلة للفتح لأعلى.</p><p dir="RTL">حجم العبوة: قنينة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق ومحرر التشغيلة</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">شركة أدوية ثايمورغان ذات المسؤولية المحدودة</p><p dir="RTL">شارع شيفجرابين 23،</p><p dir="RTL">38690 غوسلار،</p><p dir="RTL">ألمانيا</p><p dir="RTL">هاتف: 77010 (5324-49) +</p><p dir="RTL">فاكس: 770130 (5324-49) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp; الإمارات العربية المتحدة</p><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ09/2023؛ رقم النسخة Un2.0.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tiplex 15 mg Powder for Concentrate for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Tiplex 15 mg Powder for Concentrate for Solution for Infusion contains 15 mg thiotepa. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for infusion.

White lyophilized powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Tiplex is indicated, in combination with other chemotherapy medicinal products:</p><ul><li>With or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients.</li><li>When high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tiplex administration must be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.</p><p><strong><em>Posology</em></strong></p><p>Tiplex is administered at different doses, in combination with other chemotherapeutic medicinal products, in patients with haematological diseases or solid tumours prior to HPCT.</p><p>Thiotepa posology is reported, in adult and paediatric patients, according to the type of HPCT (autologous or allogeneic) and disease.</p><p><strong>Adults</strong></p><p><u>Autologous HPCT</u></p><p><em>Haematological diseases</em></p><p>The recommended dose in haematological diseases ranges from 125 mg/m<sup>2</sup>/day (3.38 mg/kg/day) to 300 mg/m<sup>2</sup>/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m<sup>2</sup>&nbsp;(24.32 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Lymphoma</li></ul><p>The recommended dose ranges from 125 mg/m<sup>2</sup>/day (3.38 mg/kg/day) to 300 mg/m<sup>2</sup>/day (8.10 mg/kg/day) as a single daily infusion, administered from 2 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 900 mg/m<sup>2</sup>&nbsp;(24.32 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Central nervous system (CNS) lymphoma</li></ul><p>The recommended dose is 185 mg/m<sup>2</sup>/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 370 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Multiple myeloma</li></ul><p>The recommended dose ranges from 150 mg/m<sup>2</sup>/day (4.05 mg/kg/day) to 250 mg/m<sup>2</sup>/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m<sup>2</sup>&nbsp;(20.27 mg/kg), during the time of the entire conditioning treatment.</p><p><em>Solid tumours</em></p><p>The recommended dose in solid tumours ranges from 120 mg/m<sup>2</sup>/day (3.24 mg/kg/day) to 250 mg/m<sup>2</sup>/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 2 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m<sup>2</sup>&nbsp;(21.62 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Breast cancer</li></ul><p>The recommended dose ranges from 120 mg/m<sup>2</sup>/day (3.24 mg/kg/day) to 250 mg/m<sup>2</sup>/day (6.76 mg/kg/day) as a single daily infusion, administered from 3 up to 5 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 800 mg/m<sup>2</sup>&nbsp;(21.62 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>CNS tumours</li></ul><p>The recommended dose ranges from 125 mg/m<sup>2</sup>/day (3.38 mg/kg/day) to 250 mg/m<sup>2</sup>/day (6.76 mg/kg/day) divided in one or two daily infusions, administered from 3 up to 4 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m<sup>2</sup>&nbsp;(20.27 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Ovarian cancer</li></ul><p>The recommended dose is 250 mg/m<sup>2</sup>/day (6.76 mg/kg/day) as a single daily infusion, administered in 2 consecutive days before autologous HPCT, without exceeding the total maximum cumulative dose of 500 mg/m<sup>2</sup>&nbsp;(13.51 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Germ cell tumours</li></ul><p>The recommended dose ranges from 150 mg/m<sup>2</sup>/day (4.05 mg/kg/day) to 250 mg/m<sup>2</sup>/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m<sup>2</sup>&nbsp;(20.27 mg/kg), during the time of the entire conditioning treatment.</p><p><u>ALLOGENEIC HPCT</u></p><p><em>Haematological diseases</em></p><p>The recommended dose in haematological diseases ranges from 185 mg/m<sup>2</sup>/day (5 mg/kg/day) to 481 mg/m<sup>2</sup>/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m<sup>2</sup>&nbsp;(15 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Lymphoma</li></ul><p>The recommended dose in lymphoma is 370 mg/m<sup>2</sup>/day (10 mg/kg/day) divided in two daily infusions before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Multiple myeloma</li></ul><p>The recommended dose is 185 mg/m<sup>2</sup>/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mg/m<sup>2</sup>&nbsp;(5 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Leukaemia</li></ul><p>The recommended dose ranges from 185 mg/m<sup>2</sup>/day (5 mg/kg/day) to 481 mg/m<sup>2</sup>/day (13 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 2 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 555 mg/m<sup>2</sup>&nbsp;(15 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Thalassemia</li></ul><p>The recommended dose is 370 mg/m<sup>2</sup>/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 370 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><p><strong>Paediatric population</strong></p><p><u>AUTOLOGOUS HPCT</u></p><p><em>Solid tumours</em></p><p>The recommended dose in solid tumours ranges from 150 mg/m<sup>2</sup>/day (6 mg/kg/day) to 350 mg/m<sup>2</sup>/day (14 mg/kg/day) as a single daily infusion, administered from 2 up to 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1 050 mg/m<sup>2</sup>&nbsp;(42 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>CNS tumours</li></ul><p>The recommended dose ranges from 250 mg/m<sup>2</sup>/day (10 mg/kg/day) to 350 mg/m<sup>2</sup>/day (14 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 1 050 mg/m<sup>2</sup>&nbsp;(42 mg/kg), during the time of the entire conditioning treatment.</p><p><u>ALLOGENEIC HPCT</u></p><p><em>Haematological diseases</em></p><p>The recommended dose in haematological diseases ranges from 125 mg/m<sup>2</sup>/day (5 mg/kg/day) to 250 mg/m<sup>2</sup>/day (10 mg/kg/day) divided in one or two daily infusions, administered from 1 up to 3 consecutive days before allogeneic HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 375 mg/m<sup>2</sup>&nbsp;(15 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Leukaemia</li></ul><p>The recommended dose is 250 mg/m<sup>2</sup>/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Thalassemia</li></ul><p>The recommended dose ranges from 200 mg/m<sup>2</sup>/day (8 mg/kg/day) to 250 mg/m<sup>2</sup>/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT without exceeding the total maximum cumulative dose of 250 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Refractory cytopenia</li></ul><p>The recommended dose is 125 mg/m<sup>2</sup>/day (5 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 375 mg/m<sup>2</sup>&nbsp;(15 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>GENETIC DISEASES</li></ul><p>The recommended dose is 125 mg/m<sup>2</sup>/day (5 mg/kg/day) as a single daily infusion, administered for 2 consecutive days before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><ul><li>Sickle cell anaemia</li></ul><p>The recommended dose is 250 mg/m<sup>2</sup>/day (10 mg/kg/day) divided in two daily infusions, administered before allogeneic HPCT, without exceeding the total maximum cumulative dose of 250 mg/m<sup>2</sup>&nbsp;(10 mg/kg), during the time of the entire conditioning treatment.</p><p><strong>Special populations </strong></p><p><u>Renal impairment</u></p><p>Studies in renally impaired patients have not been conducted. As thiotepa and its metabolites are poorly excreted in the urine, dose modification is not recommended in patients with mild or moderate renal insufficiency. However, caution is recommended (see sections 4.4 and 5.2).</p><p><u>Hepatic impairment</u></p><p>Thiotepa has not been studied in patients with hepatic impairment. Since thiotepa is mainly metabolized through the liver, caution needs to be exercised when thiotepa is used in patients with pre- existing impairment of liver function, especially in those with severe hepatic impairment. Dose modification is not recommended for transient alterations of hepatic parameters (see section 4.4).</p><p><u>Elderly</u></p><p>The administration of thiotepa has not been specifically investigated in elderly patients. However, in clinical studies, a proportion of patients over the age of 65 received the same cumulative dose as the other patients. No dose adjustment was deemed necessary.</p><p><strong><em>Method of administration</em></strong></p><p>Tiplex must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.</p><p>Each vial must be reconstituted with 1.5 ml of sterile water for injection. The total volume of reconstituted vials to be administered should be further diluted in 500 ml of sodium chloride 9 mg/ml (0.9%) solution for injection prior to administration (1000 ml if the dose is higher than 500 mg). In children, if the dose is lower than 250 mg, an appropriate volume of sodium chloride 9 mg/ml (0.9%) solution for injection may be used in order to obtain a final Tiplex concentration between 0.5 and 1 mg/ml. For instructions on reconstitution and further dilution prior to administration, see section 6.6. Precautions to be taken before handling or administering the medicinal product.</p><p>Topical reactions associated with accidental exposure to thiotepa may occur. Therefore, the use of gloves is recommended in preparing the solution for infusion. If thiotepa solution accidentally contacts the skin, the skin must be immediately thoroughly washed with soap and water. If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water (see section 6.6)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance.
Pregnancy and lactation (see section 4.6).
Concomitant use with yellow fever vaccine and with live virus and bacterial vaccines (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The consequence of treatment with thiotepa at the recommended dose and schedule is profound myelosuppression, occurring in all patients. Severe granulocytopenia, thrombocytopenia, anaemia or any combination thereof may develop. Frequent complete blood counts, including differential white blood cell counts, and platelet counts need to be performed during the treatment and until recovery is achieved. Platelet and red blood cell support, as well as the use of growth factors such as Granulocyte- colony stimulating factor (G-CSF), should be employed as medically indicated. Daily white blood cell counts and platelet counts are recommended during therapy with thiotepa and after transplant for at least 30 days.</p><p>Prophylactic or empiric use of anti-infectives (bacterial, fungal, viral) should be considered for the prevention and management of infections during the neutropenic period.</p><p>Thiotepa has not been studied in patients with hepatic impairment. Since thiotepa is mainly metabolized through the liver, caution needs to be observed when thiotepa is used in patients with pre- existing impairment of liver function, especially in those with severe hepatic impairment. When treating such patients it is recommended that serum transaminase, alkaline phosphatase and bilirubin are monitored regularly following transplant, for early detection of hepatotoxicity.</p><p>Patients who have received prior radiation therapy, greater than or equal to three cycles of chemotherapy, or prior progenitor cell transplant may be at an increased risk of hepatic veno-occlusive disease (see section 4.8).</p><p>Caution must be used in patients with history of cardiac diseases, and cardiac function must be monitored regularly in patients receiving thiotepa.</p><p>Caution must be used in patients with history of renal diseases and periodic monitoring of renal function should be considered during therapy with thiotepa.</p><p>Thiotepa might induce pulmonary toxicity that may be additive to the effects produced by other cytotoxic agents (busulfan, fludarabine and cyclophosphamide) (see section 4.8).</p><p>Previous brain irradiation or craniospinal irradiation may contribute to severe toxic reactions (e.g. encephalopathy).</p><p>The increased risk of a secondary malignancy with thiotepa, a known carcinogen in humans, must be explained to the patient.</p><p>Concomitant use with live attenuated vaccines (except yellow fever vaccines), phenytoin and fosphenytoin is not recommended (see section 4.5).</p><p>Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment. Tiplex must be delivered after the completion of any cyclophosphamide infusion (see section 4.5).</p><p>During the concomitant use of thiotepa and inhibitors of CYP2B6 or CYP3A4, patients should be carefully monitored clinically (see section 4.5).</p><p>As most alkylating agents, thiotepa might impair male or female fertility. Male patients should seek for sperm cryopreservation before therapy is started and should not father a child while treated and during the year after cessation of treatment (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Specific interactions with thiotepa</strong></p><p>Live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination.</p><p>Thiotepa appears to be metabolised via CYP2B6 and CYP3A4. Co-administration with inhibitors of CYP2B6 (for example clopidogrel and ticlopidine) or CYP3A4 (for example azole antifungals, macrolides like erythromycin, clarithromycin, telithromycin, and protease inhibitors) may increase the plasma concentrations of thiotepa and potentially decrease the concentrations of the active metabolite TEPA. Co-administration of inducers of cytochrome P450 (such as rifampicin, carbamazepine, phenobarbital) may increase the metabolism of thiotepa leading to increased plasma concentrations of the active metabolite. Therefore, during the concomitant use of thiotepa and these medicinal products, patients should be carefully monitored clinically.</p><p>Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and cyclophosphamide. CYP2B6 catalyzes the metabolic conversion of cyclophosphamide to its active form 4-hydroxycyclophosphamide (4-OHCP) and co-administration of thiotepa may therefore lead to decreased concentrations of the active 4-OHCP. Therefore, a clinical monitoring should be exercised during the concomitant use of thiotepa and these medicinal products.</p><p><strong>Contraindications of concomitant use</strong></p><p>Yellow fever vaccine: risk of fatal generalized vaccine-induced disease.</p><p>More generally, live virus and bacterial vaccines must not be administered to a patient receiving an immunosuppressive chemotherapeutic agent and at least three months must elapse between discontinuation of therapy and vaccination.</p><p><strong>Concomitant use not recommended</strong></p><p>Live attenuated vaccines (except yellow fever): risk of systemic, possibly fatal disease. This risk is increased in subjects who are already immunosuppressed by their underlying disease.</p><p>An inactivated virus vaccine should be used instead, whenever possible (poliomyelitis).</p><p>Phenytoin: risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal product or risk of toxicity enhancement and loss of efficacy of the cytotoxic medicinal product due to increased hepatic metabolism by phenytoin.</p><p><strong>Concomitant use to take into consideration </strong></p><p>Ciclosporine, tacrolimus: excessive immunosuppression with risk of lymphoproliferation.</p><p>Alkylating chemotherapeutic agents, including thiotepa, inhibit plasma pseudocholinesterase by 35% to 70%. The action of succinyl-choline can be prolonged by 5 to 15 minutes.</p><p>Thiotepa must not be concurrently administered with cyclophosphamide when both medicinal products are present in the same conditioning treatment. Tiplex must be delivered after the completion of any cyclophosphamide infusion.</p><p>The concomitant use of thiotepa and other myelosuppressive or myelotoxic agents (i.e. cyclophosphamide, melphalan, busulfan, fludarabine, treosulfan) may potentiate the risk of haematologic adverse reactions due to overlapping toxicity profiles of these medicinal products.</p><p><strong>Interaction common to all cytotoxics</strong></p><p>Due to the increase of thrombotic risk in case of malignancy, the use of anticoagulative treatment is frequent. The high intra-individual variability of the coagulation state during malignancy and the potential interaction between oral anticoagulants and anticancer chemotherapy require, if it is decided to treat the patient with oral anticoagulants, to increase the frequency of the INR (International Normalised Ratio) monitoring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential/Contraception in males and females</strong></p><p>Women of childbearing potential have to use effective contraception during treatment and a pregnancy test should be performed before treatment is started. Male patients should not father a child while treated and during the year after cessation of treatment (see section 5.3).</p><p><strong>Pregnancy</strong></p><p>There are no data on the use of thiotepa during pregnancy. In pre-clinical studies thiotepa, as most alkylating agents, has been shown to cause embryofoetal lethality and teratogenicity (see section 5.3). Therefore, thiotepa is contraindicated during pregnancy.</p><p><strong>Breast-feeding</strong></p><p>It is unknown whether thiotepa is excreted in human milk. Due to its pharmacological properties and its potential toxicity for breast-fed newborns/infants, breast-feeding is contraindicated during treatment with thiotepa.</p><p><strong>Fertility</strong></p><p>As most alkylating agents, thiotepa might impair male and female fertility. Male patients should seek for sperm cryopreservation before therapy is started (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tiplex has major influence on the ability to drive and use machines. It is likely that certain adverse reactions of thiotepa like dizziness, headache and blurred vision could affect these functions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>The safety of thiotepa has been examined through a review of adverse events reported in published data from clinical trials. In these studies, a total of 6 588 adult patients and 902 paediatric patients received thiotepa for conditioning treatment prior to haematopoietic progenitor cell transplantation.</p><p>Serious toxicities involving the haematologic, hepatic and respiratory systems were considered as expected consequences of the conditioning regimen and transplant process. These include infection and Graft-versus host disease (GvHD) which, although not directly related, were the major causes of morbidity and mortality, especially in allogeneic HPCT.</p><p>The most frequently adverse reactions reported in the different conditioning treatments including thiotepa are: infections, cytopenia, acute GvHD and chronic GvHD, gastrointestinal disorders, haemorrhagic cystitis and mucosal inflammation.</p><p><em>Leukoencephalopathy</em></p><p>Cases of leukoencephalopathy have been observed following treatment with thiotepa in adult and paediatric patients with multiple previous chemotherapies, including methotrexate and radiotherapy. Some cases had a fatal outcome.</p><p><strong>Tabulated list of adverse reactions</strong></p><p><em>Adults</em></p><p>The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in adult patients as more than an isolated case, are listed below by system organ class and by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:1066px"><tbody><tr><td style="vertical-align:top; width:299px"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:225px"><p><strong>Very common</strong></p></td><td style="vertical-align:top; width:212px"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:147px"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:181px"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top; width:299px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:225px"><p>Infection susceptibility increased</p><p>Sepsis</p></td><td style="vertical-align:top; width:212px">&nbsp;</td><td style="vertical-align:top; width:147px"><p>Toxic shock syndrome</p></td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top; width:225px">&nbsp;</td><td style="vertical-align:top; width:212px"><p>Treatment related second malignancy</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:225px"><p>Leukopenia</p><p>Thrombocytopenia</p><p>Febrile neutropenia</p><p>Anaemia</p><p>Pancytopenia</p><p>Granulocytopenia</p></td><td style="vertical-align:top; width:212px">&nbsp;</td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:225px"><p>Acute graft versus host disease</p><p>Chronic graft versus host disease</p></td><td style="vertical-align:top; width:212px"><p>Hypersensitivity</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Endocrine disorders</p></td><td style="vertical-align:top; width:225px">&nbsp;</td><td style="vertical-align:top; width:212px"><p>Hypopituitarism</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:225px"><p>Anorexia</p><p>Decreased appetite</p><p>Hyperglycaemia</p></td><td style="vertical-align:top; width:212px">&nbsp;</td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:225px"><p>Confusional state</p><p>Mental status changes</p></td><td style="vertical-align:top; width:212px"><p>Anxiety</p></td><td style="vertical-align:top; width:147px"><p>Delirium</p><p>Nervousness</p><p>Hallucination</p><p>Agitation</p></td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:225px"><p>Dizziness</p><p>Headache</p><p>Vision blurred</p><p>Encephalopathy</p><p>Convulsion</p><p>Paraesthesia</p></td><td style="vertical-align:top; width:212px"><p>Intracranial aneurysm</p><p>Extrapyramidal disorder</p><p>Cognitive disorder</p><p>Cerebral haemorrhage</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px"><p>Leukoencephalopathy</p></td></tr><tr><td style="vertical-align:top; width:299px"><p>Eye disorders</p></td><td style="vertical-align:top; width:225px"><p>Conjunctivitis</p></td><td style="vertical-align:top; width:212px"><p>Cataract</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:225px"><p>Hearing impaired</p><p>Ototoxicity</p><p>Tinnitus</p></td><td style="vertical-align:top; width:212px">&nbsp;</td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:225px"><p>Arrhythmia</p></td><td style="vertical-align:top; width:212px"><p>Tachycardia</p><p>Cardiac failure</p></td><td style="vertical-align:top; width:147px"><p>Cardiomyopathy</p><p>Myocarditis</p></td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:225px"><p>Lymphoedema</p><p>Hypertension</p></td><td style="vertical-align:top; width:212px"><p>Haemorrhage</p><p>Embolism</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:225px"><p>Idiopathic pneumonia syndrome</p><p>Epistaxis</p></td><td style="vertical-align:top; width:212px"><p>Pulmonary oedema</p><p>Cough</p><p>Pneumonitis</p></td><td style="vertical-align:top; width:147px"><p>Hypoxia</p></td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:225px"><p>Nausea</p><p>Stomatitis</p><p>Oesophagitis</p><p>Vomiting</p><p>Diarrhoea</p><p>Dyspepsia</p><p>Abdominal pain</p><p>Enteritis</p><p>Colitis</p></td><td style="vertical-align:top; width:212px"><p>Constipation</p><p>Gastrointestinal perforation</p><p>Ileus</p></td><td style="vertical-align:top; width:147px"><p>Gastrointestinal ulcer</p></td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:225px"><p>Venoocclusive liver disease</p><p>Hepatomegaly</p><p>Jaundice</p></td><td style="vertical-align:top; width:212px">&nbsp;</td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:225px"><p>Rash</p><p>Pruritus</p><p>Alopecia</p></td><td style="vertical-align:top; width:212px"><p>Erythema</p></td><td style="vertical-align:top; width:147px"><p>Pigmentation disorder</p><p>Erythrodermic psoriasis</p></td><td style="vertical-align:top; width:181px"><p>Severe toxic skin reactions including cases of Stevens-Johnson syndrome and toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:top; width:299px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:225px"><p>Back pain</p><p>Myalgia</p><p>Arthralgia</p></td><td style="vertical-align:top; width:212px">&nbsp;</td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:225px"><p>Cystitis haemorrhagic</p></td><td style="vertical-align:top; width:212px"><p>Dysuria</p><p>Oliguria</p><p>Renal failure</p><p>Cystitis</p><p>Haematuria</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:225px"><p>Azoospermia</p><p>Amenorrhoea</p><p>Vaginal haemorrhage</p></td><td style="vertical-align:top; width:212px"><p>Menopausal symptoms</p><p>Infertility female</p><p>Infertility male</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:225px"><p>Pyrexia</p><p>Asthenia</p><p>Chills</p><p>Generalised oedema</p><p>Injection site inflammation</p><p>Injection site pain</p><p>Mucosal inflammation</p></td><td style="vertical-align:top; width:212px"><p>Multi-organ failure</p><p>Pain</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:299px"><p>Investigations</p></td><td style="vertical-align:top; width:225px"><p>Weight increased</p><p>Blood bilirubin increased</p><p>Transaminases increased</p><p>Blood amylase increased</p></td><td style="vertical-align:top; width:212px"><p>Blood creatinine increased</p><p>Blood urea increased</p><p>Gamma-glutamyltransferase increased</p><p>Blood alkaline phosphatase increased</p><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top; width:147px">&nbsp;</td><td style="vertical-align:top; width:181px">&nbsp;</td></tr></tbody></table><p><em>Paediatric population</em></p><p>The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in paediatric patients as more than an isolated case, are listed below by system organ class and by frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:1054px"><tbody><tr><td style="vertical-align:top; width:319px"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:255px"><p><strong>Very common</strong></p></td><td style="vertical-align:top; width:221px"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:255px"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:255px"><p>Infection susceptibility increased</p><p>Sepsis</p></td><td style="vertical-align:top; width:221px"><p>Thrombocytopenic purpura</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top; width:255px">&nbsp;</td><td style="vertical-align:top; width:221px"><p>Treatment related second malignancy</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:255px"><p>Thrombocytopenia</p><p>Febrile neutropenia</p><p>Anaemia</p><p>Pancytopenia</p><p>Granulocytopenia</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:255px"><p>Acute graft versus host disease</p><p>Chronic graft versus host disease</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Endocrine disorders</p></td><td style="vertical-align:top; width:255px"><p>Hypopituitarism</p><p>Hypogonadism</p><p>Hypothyroidism</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:255px"><p>Anorexia</p><p>Hyperglycaemia</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:255px"><p>Mental status changes</p></td><td style="vertical-align:top; width:221px"><p>Mental disorder due to a general medical condition</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:255px"><p>Headache</p><p>Encephalopathy</p><p>Convulsion</p><p>Cerebral haemorrhage</p><p>Memory impairment</p><p>Paresis</p></td><td style="vertical-align:top; width:221px"><p>Ataxia</p></td><td style="vertical-align:top; width:255px"><p>Leukoencephalopathy</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:255px"><p>Hearing impaired</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:255px"><p>Cardiac arrest</p></td><td style="vertical-align:top; width:221px"><p>Cardiovascular insufficiency</p><p>Cardiac failure</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:255px"><p>Haemorrhage</p></td><td style="vertical-align:top; width:221px"><p>Hypertension</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:255px"><p>Pneumonitis</p></td><td style="vertical-align:top; width:221px"><p>Idiopathic pneumonia syndrome</p><p>Pulmunary haemorrage</p><p>Pulmonary oedema</p><p>Epistaxis</p><p>Hypoxia</p><p>Respiratory arrest</p></td><td style="vertical-align:top; width:255px"><p>Pulmonary arterial hypertension</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:255px"><p>Nausea</p><p>Stomatitis</p><p>Vomiting</p><p>Diarrhoea</p><p>Abdominal pain</p></td><td style="vertical-align:top; width:221px"><p>Enteritis</p><p>Intestinal obstruction</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:255px"><p>Venoocclusive liver disease</p></td><td style="vertical-align:top; width:221px"><p>Liver failure</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:255px"><p>Rash</p><p>Erythema</p><p>Desquamation</p><p>Pigmentation disorder</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px"><p>Severe toxic skin reactions including cases of Stevens-Johnson syndrome and toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:top; width:319px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:255px"><p>Growth retardation</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:255px"><p>Bladder disorders</p></td><td style="vertical-align:top; width:221px"><p>Renal failure</p><p>Cystitis haemorrhagic</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:255px"><p>Pyrexia</p><p>Mucosal inflammation</p><p>Pain</p><p>Multi-organ failure</p></td><td style="vertical-align:top; width:221px">&nbsp;</td><td style="vertical-align:top; width:255px">&nbsp;</td></tr><tr><td style="vertical-align:top; width:319px"><p>Investigations</p></td><td style="vertical-align:top; width:255px"><p>Blood bilirubin increased</p><p>Transaminases increased</p><p>Blood creatinine increased</p><p>Aspartate aminotransferase increased</p><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top; width:221px"><p>Blood urea increased</p><p>Blood electrolytes abnormal</p><p>Prothrombin time ratio increased</p></td><td style="vertical-align:top; width:255px">&nbsp;</td></tr></tbody></table><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Center (NPC)</p><p>SFDA Call Center: 19999</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdoses of thiotepa. The most important adverse reactions expected in case of overdose is myeloablation and pancytopenia.</p><p>There is no known antidote for thiotepa.</p><p>The haematological status needs to be closely monitored and vigorous supportive measures instituted as medically indicated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, ATC code: L01AC01</p><p><strong>Mechanism of action</strong></p><p>Thiotepa is a polyfunctional cytotoxic agent related chemically and pharmacologically to the nitrogen mustard. The radiomimetic action of thiotepa is believed to occur through the release of ethylene imine radicals that, as in the case of irradiation therapy, disrupt the bonds of DNA, e.g. by alkylation of guanine at the N-7, breaking the linkage between the purine base and the sugar and liberating alkylated guanine.</p><p><strong>Clinical safety and efficacy</strong></p><p>The conditioning treatment must provide cytoreduction and ideally disease eradication. Thiotepa has marrow ablation as its dose-limiting toxicity, allowing significant dose escalation with the infusion of autologous HPCT. In allogeneic HPCT, the conditioning treatment must be sufficiently immunosuppressive and myeloablative to overcome host rejection of the graft. Due to its highly myeloablative characteristics, thiotepa enhances recipient immunosuppression and myeloablation, thus strengthening engraftment; this compensates for the loss of the GvHD-related GvL effects. As alkylating agent, thiotepa produces the most profound inhibition of tumour cell growth&nbsp;<em>in vitro&nbsp;</em>with the smallest increase in medicinal product concentration. Due to its lack of extramedullary toxicity despite dose escalation beyond myelotoxic doses, thiotepa has been used for decades in combination with other chemotherapy medicinal products prior to autologous and allogeneic HPCT.</p><p>The results of published clinical studies supporting the efficacy of thiotepa are summarised:</p><p><u>Autologous HPCT</u></p><p><em>Haematological diseases</em></p><p>Engraftment:<em>&nbsp;</em>Conditioning treatments including thiotepa have proved to be myeloablative.&nbsp;<em>Disease free survival (DFS):&nbsp;</em>An estimated 43% at five years has been reported, confirming that conditioning treatments containing thiotepa following autologous HPCT are effective therapeutic strategies for treating patients with haematological diseases.</p><p>Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being 60% or lower, which was considered by the physicians as the threshold to prove efficacy. In some of the conditioning treatments evaluated, relapse rates lower than 60% have also been reported at 5 years.</p><p>Overall survival (OS):&nbsp;OS ranged from 29% to 87% with a follow-up ranging from 22 up to 63 months.</p><p>Regimen related mortality (RRM)&nbsp;and&nbsp;Transplant related mortality (TRM): RRM values ranging from 2.5% to 29% have been reported. TRM values ranged from 0% to 21% at 1 year, confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with haematological diseases.</p><p><em>Solid tumours</em></p><p>Engraftment:&nbsp;Conditioning treatments including thiotepa have proved to be myeloablative.</p><p><em>Disease free survival (DFS):&nbsp;</em>Percentages reported with follow-up periods of more than 1 year confirm that conditioning treatments containing thiotepa following autologous HPCT are effective choices for treating patients with solid tumours.</p><p>Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being lower than 60%, which was considered by the physicians as the threshold to prove efficacy. In some cases, relapse rates of 35% and of 45% have been reported at 5 years and 6 years respectively.</p><p>Overall survival:<em>&nbsp;</em>OS ranged from 30% to 87% with a follow-up ranging from 11.7 up to 87 months.&nbsp;<em>Regimen related mortality (RRM)&nbsp;</em>and&nbsp;<em>Transplant related mortality (TRM)</em>: RRM values ranging from 0% to 2% have been reported. TRM values ranged from 0% to 7.4% confirming the safety of the conditioning treatment including thiotepa for autologous HPCT in adult patients with solid tumours.</p><p><u>Allogeneic HPCT</u></p><p><em>Haematological diseases</em></p><p>Engraftment:<em>&nbsp;</em>Engraftment has been achieved (92%-100%) in all reported conditioning treatments and it was considered to occur at the expected time. Therefore it can be concluded that conditioning treatments including thiotepa are myeloablative.</p><p>GvHD (graft versus host disease):&nbsp;all conditioning treatments evaluated assured a low incidence of acute GvHD grade III-IV (from 4% to 24%).</p><p>Disease free survival (DFS):<em>&nbsp;</em>Percentages reported with follow-up periods of more than 1 year and up to 5 years confirm that conditioning treatments containing thiotepa following allogeneic HPCT are effective choices for treating patients with haematological diseases.</p><p>Relapse: In all conditioning treatments containing thiotepa, relapse rates at more than 1 year have been reported as being lower than 40% (which was considered by the physicians as the threshold to prove efficacy). In some cases, relapse rates lower than 40% have also been reported at 5 years and 10 years.&nbsp;<em>Overall survival:&nbsp;</em>OS ranged from 31% to 81% with a follow-up ranging from 7.3 up to 120 months.</p><p>Regimen related mortality (RRM)&nbsp;and&nbsp;Transplant related mortality&nbsp;(TRM): low values have been reported, confirming the safety of the conditioning treatments including thiotepa for allogeneic HPCT in adult patients with haematological diseases.</p><p><strong>Paediatric population</strong></p><p><u>Autologous HPCT</u></p><p><em>Solid tumours</em></p><p>Engraftment:&nbsp;It has been achieved with all reported conditioning regimens including thiotepa.</p><p>Disease free survival (DFS):<em>&nbsp;</em>With a follow-up of 36 to 57 months, DFS ranged from 46% to 70% in the reported studies. Considering that all patients were treated for high risk solid tumours, DFS results confirm that conditioning treatments containing thiotepa following autologous HPCT are effective therapeutic strategies for treating paediatric patients with solid tumours.</p><p>Relapse: In all the reported conditioning regimens containing thiotepa, relapse rates at 12 to 57 months ranged from 33% to 57%. Considering that all patients suffer of recurrence or poor prognosis solid tumours, these rates support the efficacy of conditioning regimens based on thiotepa.</p><p>Overall survival (OS):<em>&nbsp;</em>OS ranged from 17% to 84% with a follow-up ranging from 12.3 up to 99.6 months.</p><p>Regimen related mortality (RRM)&nbsp;and&nbsp;Transplant related mortality&nbsp;(TRM): RRM values ranging from 0% to 26.7% have been reported. TRM values ranged from 0% to 18% confirming the safety of the conditioning treatments including thiotepa for autologous HPCT in paediatric patients with solid tumours.</p><p><u>Allogeneic HPCT</u></p><p><em>Haematological diseases</em></p><p>Engraftment:&nbsp;It has been achieved with all evaluated conditioning regimens including thiotepa with a success rate of 96% - 100%. The haematological recovery is in the expected time.</p><p>Disease free survival (DFS):&nbsp;Percentages of 40% - 75% with follow-up of more than 1 year have been reported. DFS results confirm that conditioning treatment containing thiotepa following allogeneic HPCT are effective therapeutic strategies for treating paediatric patients with haematological diseases.&nbsp;<em>Relapse:&nbsp;</em>In all the reported conditioning regimens containing thiotepa, the relapse rate was in the range of 15% - 44%. These data support the efficacy of conditioning regimens based on thiotepa in all haematological diseases.</p><p>Overall survival (OS):&nbsp;OS ranged from 50% to 100% with a follow-up ranging from 9.4 up to 121 months.</p><p>Regimen related mortality (RRM)&nbsp;and&nbsp;Transplant related mortality&nbsp;(TRM): RRM values ranging from 0% to 2.5% have been reported. TRM values ranged from 0% to 30% confirming the safety of the conditioning treatment including thiotepa for allogeneic HPCT in paediatric patients with haematological diseases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Thiotepa is unreliably absorbed from the gastrointestinal tract: acid instability prevents thiotepa from being administered orally.</p><p><strong>Distribution</strong></p><p>Thiotepa is a highly lipophilic compound. After intravenous administration, plasma concentrations of the active substance fit a two compartment model with a rapid distribution phase. The volume of distribution of thiotepa is large and it has been reported as ranging from 40.8 l/m<sup>2</sup>&nbsp;to 75 l/m<sup>2</sup>, indicating distribution to total body water. The apparent volume of distribution of thiotepa appears independent of the administered dose. The fraction unbound to proteins in plasma is 70-90%; insignificant binding of thiotepa to gamma globulin and minimal albumin binding (10-30%) has been reported.</p><p>After intravenous administration, CSF medicinal product exposure is nearly equivalent to that achieved in plasma; the mean ratio of AUC in CSF to plasma for thiotepa is 0.93. CSF and plasma concentrations of TEPA, the first reported active metabolite of thiotepa, exceed the concentrations of the parent compound.</p><p><strong>Biotransformation</strong></p><p>Thiotepa undergoes rapid and extensive hepatic metabolism and metabolites could be detected in urine within 1 hour after infusion. The metabolites are active alkylating agents but the role they play in the antitumor activity of thiotepa remains to be elucidated. Thiotepa undergoes oxidative desulphuration via the cytochrome P450 CYP2B and CYP3A isoenzyme families to the major and active metabolite TEPA (triethylenephosphoramide). The total excreted amount of thiotepa and its identified metabolites accounts for 54-100% of the total alkylating activity, indicating the presence of other alkylating metabolites. During conversion of GSH conjugates to N-acetylcysteine conjugates, GSH, cysteinylglycine, and cysteine conjugates are formed. These metabolites are not found in urine, and, if formed, are probably excreted in bile or as intermediate metabolites rapidly converted into thiotepa-mercapturate.</p><p><strong>Elimination</strong></p><p>The total clearance of thiotepa ranged from 11.4 to 23.2 l/h/m<sup>2</sup>. The elimination half-life varied from 1.5 to 4.1 hours. The identified metabolites TEPA, monochlorotepa and thiotepa-mercapturate are all excreted in the urine. Urinary excretion of thiotepa and TEPA is nearly complete after 6 and 8 hours respectively. The mean urinary recovery of thiotepa and its metabolites is 0.5% for the unchanged medicinal product and monochlorotepa, and 11% for TEPA and thiotepa-mercapturate.</p><p><strong>Linearity/non-linearity</strong></p><p>There is no clear evidence of saturation of metabolic clearance mechanisms at high doses of thiotepa.</p><p><strong>Special populations</strong></p><p><em>Paediatric population</em></p><p>The pharmacokinetics of high dose thiotepa in children between 2 and 12 years of age do not appear to vary from those reported in children receiving 75 mg/m<sup>2</sup>&nbsp;or adults receiving similar doses.</p><p><em>Renal impairment</em></p><p>The effects of renal impairment on thiotepa elimination have not been assessed.</p><p><em>Hepatic impairment</em></p><p>The effects of hepatic impairment on thiotepa metabolism and elimination have not been assessed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>No conventional acute and repeat dose toxicity studies were performed.</li><li>Thiotepa was shown to be genotoxic&nbsp;<em>in vitro&nbsp;</em>and&nbsp;<em>in vivo</em>, and carcinogenic in mice and rats.</li><li>Thiotepa was shown to impair fertility and interfere with spermatogenesis in male mice, and to impair ovarian function in female mice. It was teratogenic in mice and in rats, and foeto-lethal in rabbits. These effects were seen at doses lower than those used in humans.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tiplex is unstable in acid medium.</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months. 
After reconstitution
Chemical and physical in-use stability after reconstitution has been demonstrated for 8 hours when stored at 2-8°C.
After dilution
Chemical and physical in-use stability after dilution has been demonstrated for 24 hours when stored at 2-8°C and for 4 hours when stored at 25°C. 

From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than the above mentioned conditions when dilution has taken place in controlled and validated aseptic conditions.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2-8&deg;C). Avoid freeze.</p><p>Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I clear colorless glass vials with gray stoppers and dark blue flip-off caps.</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Preparation of Tiplex</strong></p><p>Procedures for proper handling and disposal of anticancer medicinal products must be considered. All transfer procedures require strict adherence to aseptic techniques, preferably employing a vertical laminar flow safety hood.</p><p>As with other cytotoxic compounds, caution needs to be exercised in handling and preparation of Tiplex solutions to avoid accidental contact with skin or mucous membranes. Topical reactions associated with accidental exposure to thiotepa may occur. In fact, the use of gloves is recommended in preparing the solution for infusion. If thiotepa solution accidentally contacts the skin, the skin must be immediately and thoroughly washed with soap and water. If thiotepa accidentally contacts mucous membranes, they must be flushed thoroughly with water.</p><p><strong>Reconstitution</strong></p><p>Tiplex must be reconstituted with 1.5 ml of sterile water for injection.</p><p>Using a syringe fitted with a needle, aseptically withdraw 1.5 ml of sterile water for injection.</p><p>Inject the content of the syringe into the vial through the rubber stopper.</p><p>Remove the syringe and the needle and mix manually by repeated inversions.</p><p>Only colourless solutions, without any particulate matter, must be used. Reconstituted solutions may occasionally show opalescence; such solutions can still be administered.</p><p><strong>Further dilution in the infusion bag</strong></p><p>The reconstituted solution is hypotonic and must be further diluted prior to administration with 500 ml sodium chloride 9 mg/ml (0.9%) solution for injection (1000 ml if the dose is higher than 500 mg) or with an appropriate volume of sodium chloride 9 mg/ml (0.9%) in order to obtain a final Tiplex concentration between 0.5 and 1 mg/ml.</p><p><strong>Administration</strong></p><p>Tiplex infusion solution should be inspected visually for particulate matter prior to administration. Solutions containing a precipitate should be discarded.</p><p>Prior to and following each infusion, the indwelling catheter line should be flushed with approximately 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection.</p><p>The infusion solution must be administered to patients using an infusion set equipped with a 0.2 &micro;m in-line filter. Filtering does not alter solution potency.</p><p><strong>Disposal</strong></p><p>Tiplex is for single use only.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 4980170            
Fax: + (966-11) 4980187
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 December 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>